Latest news with #NeumoraTherapeutics
Globe and Mail
6 days ago
- Health
- Globe and Mail
Major Depressive Disorder Pipeline Appears Robust With 75+ Key Companies Actively Working in the Therapeutics Segment
DelveInsight's 'Major Depressive Disorder Pipeline Insight 2025' report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Major Depressive Disorder Pipeline. Dive into DelveInsight's comprehensive report today! @ Major Depressive Disorder Pipeline Outlook Key Takeaways from the Major Depressive Disorder Pipeline Report In May 2025, Biohaven Therapeutics Ltd announced a study to determine the efficacy and safety of BHV-7000 in participants with Major Depressive Disorder (MDD). In May 2025, Neurocrine Biosciences conducted a study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression. In May 2025, Neumora Therapeutics, Inc. organized a study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501). In May 2025, Otsuka Pharmaceutical Development & Commercialization, Inc. announced a phase 2 study parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD). In May 2025, Janssen Research & Development LLC announced a study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD). DelveInsight's Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment. The leading Major Depressive Disorder Companies such as GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others. Promising Major Depressive Disorder Pipeline Therapies such as NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others. Stay ahead with the most recent pipeline outlook for Major Depressive Disorder. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Major Depressive Disorder Medication Major Depressive Disorder Emerging Drugs Profile SAGE-217: Sage Therapeutics SAGE-217 is an investigational, oral, novel medicine in development for depression. SAGE-217 is an investigational oral neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM). The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. Biogen and Sage Therapeutics have submitted a new drug application (NDA) to the FDA for zuranolone for the treatment of major depressive disorder (MDD). REL-1017: Relmada Therapeutics Inc. REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with MDD. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. REL-1017, has entered its Phase 3 registration program as an adjunctive treatment for MDD. Seltorexant: Minerva Sciences Seltorexant is an innovative selective orexin 2 receptor antagonist under development for the treatment of insomnia and related mood disorders. Insomnia is the repeated difficulty with sleep initiation, maintenance or quality that occurs despite adequate time and opportunity for sleep, resulting in daytime impairment. The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development. SP-624: Sirtsei Pharmaceuticals, Inc. SP-624 is being studied in phase II stage of development for the treatment of major depressive disorder in comparison with placebo by Sirtsei Pharmaceuticals, Inc. SPL026: Small Pharma SPL026 (DMT), is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the world's first DMT clinical trial for depression, in collaboration with Imperial College London. PDC-1421: BioLite Inc. PDC-1421 (BLI-1005) is a Norepinephrine plasma membrane transport protein inhibitor being developed by BioLite Inc, for the treatment of major depressive disorder. The drug is currently in phase II stage of development. The Major Depressive Disorder Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Major Depressive Disorder with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Major Depressive Disorder Medication. Major Depressive Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Major Depressive Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Major Depressive Disorder market Explore groundbreaking therapies and clinical trials in the Major Depressive Disorder Medication. Access DelveInsight's detailed report now! @ New Major Depressive Disorder Drugs Major Depressive Disorder Companies GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others. Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Subcutaneous Intravenous Intramuscular Major Depressive Disorder Products have been categorized under various Molecule types such as Bispecific Antibody Peptides Small molecule Gene therapy Unveil the future of Major Depressive Disorder Medication. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Major Depressive Disorder Market Drivers and Barriers Scope of the Major Depressive Disorder Pipeline Report Coverage- Global Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals and others. Major Depressive Disorder Pipeline Therapies- NMRA-335140 Aticaprant, NBI-1065845, CYB003, Azetukalner, GW679769, BHV-7000 and others. Major Depressive Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Major Depressive Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Major Depressive Disorder Medication and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Major Depressive Disorder Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Major Depressive Disorder: Overview Pipeline Therapeutics Therapeutic Assessment Major Depressive Disorder – DelveInsight's Analytical Perspective Late Stage Products (Preregistration) SAGE-217: Sage Therapeutics Drug profiles in the detailed report….. Mid Stage Products (Phase II) SP-624: Sirtsei Pharmaceuticals, Inc. Drug profiles in the detailed report….. Early Stage Products (Phase I/II) SPL026: Small Pharma Drug profiles in the detailed report….. Preclinical Stage Products Drug Name: Company name Drug profiles in the detailed report….. Inactive Products Major Depressive Disorder Key Companies Major Depressive Disorder Key Products Major Depressive Disorder- Unmet Needs Major Depressive Disorder- Market Drivers and Barriers Major Depressive Disorder- Future Perspectives and Conclusion Major Depressive Disorder Analyst Views Major Depressive Disorder Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Associated Press
01-04-2025
- Business
- Associated Press
NEUMORA THERAPEUTICS, INC. (NASDAQ: NMRA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Neumora Therapeutics, Inc. Investors of Upcoming Deadline
NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA)? Did you purchase your shares in connection with the Company's September 15, 2023 IPO? Did you lose money in your investment in Neumora Therapeutics, Inc.? Do you want to discuss your rights? Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Neumora Therapeutics, Inc. ('Neumora' or the 'Company') (NASDAQ: NMRA) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. If you purchased or acquired Neumora stock, and/or would like to discuss your legal rights and options please visit Neumora Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected]. A lawsuit was filed in the United States District Court for the Southern District of New York on behalf of investors who purchased or acquired the stock of Neumora pursuant and/or traceable to the offering documents issued in connection with the initial public offering ('IPO') held on or about September 15, 2023, inclusive, alleging violations of the Securities Act of 1933 against the Company and certain of its senior officers. According to the lawsuit, Defendants made misrepresentations concerning risks and uncertainties known by the Company at the time of the IPO regarding the Phase Three Program for Navacaprant, its flagship drug candidate. If you wish to serve as lead plaintiff for the Class, you must file papers by April 7, 2025. A lead plaintiff is a representative party acting on other class members' behalf in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of class actions, the Firm has been named to The National Law Journal's 'Plaintiffs' Hot List' thirteen times and listed in The Legal 500 for sixteen consecutive years. ATTORNEY ADVERTISING. © 2025 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter. Contact Information: Peter Allocco
Associated Press
25-02-2025
- Business
- Associated Press
ROSEN, LEADING INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the 'Offering Documents') issued in connection with Neumora's September 2023 initial public offering (the 'IPO'), of the important April 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Neumora common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Neumora class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, the Offering Documents contained false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial inclusion criteria to include a patient population with moderate to severe major depressive disorder ('MDD') to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) and to that same end, Neumora also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Neumora class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653
Yahoo
14-02-2025
- Business
- Yahoo
Hutchmed price target raised to $27 from $26 at BofA
BofA raised the firm's price target on Hutchmed (HCM) to $27 from $26 and keeps a Buy rating on the shares. While noting it sees 'some regulatory headwinds potentially ahead,' the firm keeps a Buy rating on the shares and cites higher revenue expectations for key assets after 'strong performance in 2024' for its revised price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on HCM: Hutchmed announces NMPA approval for Orpathys supplemental new drug application Hutchmed price target lowered to $26 from $30 at BofA Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint Hutchmed announces NDA acceptance in China, payment from AstraZeneca Hutchmed divests 45% interest in Shanghai Hutchison for $608M Sign in to access your portfolio
